About: Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Jienchi Dorward et al published July 2018 in The lancet. HIV

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 2018 (uk) im Juli 2018 veröffentlichter wissenschaftlicher Artikel (de) article by Jienchi Dorward et al published July 2018 in The lancet. HIV (en)
publication date	wds:Q58038937-DAB3D8A3-3D12-4772-AAF3-5A58FA4C64A2
publication date	2018-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58038937-82C053C0-B6EA-4C8E-AE14-D79A61614124
language of work or name	English
cites work	wds:Q58038937-02EBFA9D-EC7B-47B6-BB06-74F7B771B3DC wds:Q58038937-12E65FC7-D049-4525-8E11-32C888C544C5 wds:Q58038937-12F5BCF7-8AE4-4120-8C34-228EE6D14518 wds:Q58038937-1BC4E9C6-FD33-4516-A71B-58DC18B28C5D wds:Q58038937-2B673076-1163-4915-96B6-77A32CDD42AA wds:Q58038937-3E5E6519-ECFD-4AAF-A664-2DE7D18C0C1E wds:Q58038937-4EBCB8C8-0E07-4CD3-A13C-189BEEE85D3F wds:Q58038937-564C00E1-9D17-4D1E-8DB1-90C1AF609002 wds:Q58038937-57A873FD-22F0-4C49-985B-2B4CC6F1167D wds:Q58038937-638EC1B2-CEA9-4982-A433-90DD4DF8F9D8 wds:Q58038937-66564785-8B15-479E-B440-CA8A7CFF792F wds:Q58038937-6BD7459A-F89B-4137-B505-788FDB923FC8 wds:Q58038937-70C0288B-1A1A-4FC5-8855-BB779F2AC4FC wds:Q58038937-753E2083-C3B8-48DB-8140-C311944C82E5 wds:Q58038937-7FA4F132-BBCF-44F5-B359-1E4C250911C2 wds:Q58038937-87F66F09-F2AF-48ED-B5C8-A4CFFCE51130 wds:Q58038937-8CDFFC86-5FEC-46BB-8710-9D8D6249ABF0 wds:Q58038937-8FBA6318-611D-425B-BBF3-D15F619DD018 wds:Q58038937-9520FD5C-12F6-4622-9C52-9BF065CA56F0 wds:Q58038937-95F038CF-518B-42A9-A62F-B7ADEF43F7AC wds:Q58038937-AA6636AF-F8E8-4B4B-A6C0-A6BCF702FDEF wds:Q58038937-ADCCBBAA-9C6D-4D22-990A-E5724B514A0C wds:Q58038937-B0668F46-E602-42F8-96F1-2091561D8992 wds:Q58038937-B1350559-C46B-4851-940B-0E1215B1E08A wds:Q58038937-B2C47761-A94F-496B-8807-A24EA5E25390 wds:Q58038937-B39C642D-FE8F-4758-A8A4-D8C17037BCBC wds:Q58038937-B45468A1-1B47-4C22-8E0A-98B0CCF94B64 wds:Q58038937-B6D787D5-CF1B-4D8B-A5EB-3CA3E3007607 wds:Q58038937-BC27A12C-F3FE-4C0D-93A4-69AFB8558E44 wds:Q58038937-C26A9D25-C60C-4857-9946-736DADB9FEE3 wds:Q58038937-CC1F7D7E-9448-40C3-9A29-22706EB9D3C5 wds:Q58038937-D730E900-4A0F-4D96-80EA-6CA6DD85C4EC wds:Q58038937-D8FF9647-4C31-4F25-97CA-046225815981 wds:Q58038937-E165BC8A-4DC6-4743-9D00-789C50183FB5 wds:Q58038937-EE781395-A606-485C-A07D-F90836C53909 wds:Q58038937-FFE6292F-8390-4FBA-922A-F4FAF8E00447
cites work	Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection Assessment of second-line antiretroviral regimens for HIV therapy in Africa Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study Viral load monitoring as a tool to reinforce adherence: a systematic review Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study Emergent drug resistance with integrase strand transfer inhibitor-based regimens High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa HIV drug resistance against strand transfer integrase inhibitors Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors on people living with HIV who have pre-existing nucleoside reverse transcriptase inhibitor mutations. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients With Nucleoside Reverse Transcriptase Inhibitor Resistance. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study Point-of-care viral load testing and differentiated HIV care. The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine. Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings Actionable adherence monitoring to optimise intervention. The unexpected success of NRTIs in second-line treatment. Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.
author name string	wds:Q58038937-CC00F360-4E0C-44B3-B7F5-1108CCA5A2C8 wds:Q58038937-DFF06EB3-76A2-4F47-9430-CB99ABA7EAE7
author name string	Paul K Drain Yogan Pillay
rdfs:label	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (en) Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (nl)
skos:prefLabel	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (en) Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (nl)
name	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (en) Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research (nl)
author	wds:Q58038937-2CFA7D8C-8EFA-4375-B61F-189B681CB890 wds:Q58038937-5A87268D-A4BC-47D0-87AC-619717E79F91 wds:Q58038937-6C4B3A17-29FC-4E5C-AB2E-A75CB7E3EFA3 wds:Q58038937-AA55C01C-3078-4C39-B096-7869F7FF1721 wds:Q58038937-C422423A-DCD1-43D9-82B2-99B39A916212 wds:Q58038937-CB5206AF-AD66-4404-A6F6-6AB028016DDF
author	Salim Abdool Karim Túlio de Oliveira Nigel Garrett

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software